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New WHO recommendations on intraoperative and postoperative measures for 1 
surgical site infection prevention: an evidence-based global perspective 2 
This is the second in a Series of two papers about surgical site infections. 3 
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1 Table and 1 Figure 47 
Table 1: Summary of the WHO recommendations for intraoperative and postoperative measures to 48 
prevent SSIs* 49 
Figure 1: Patient receiving oxygen in the immediate postoperative period. Courtesy of Shutterstock.  50 
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ABSTRACT 51 
Surgical site infections (SSIs) are the most common health-care-associated infections in developing 52 
countries, but they also represent a substantial epidemiological burden in high-income countries. 53 
The prevention of these infections is complex and requires the integration of a range of preventive 54 
measures before, during, and after surgery. No international guidelines are available and 55 
inconsistencies in the interpretation of evidence and recommendations in national guidelines have 56 
been identified. Considering the prevention of SSIs as a priority for patient safety, WHO has 57 
developed evidence-based and expert consensus-based recommendations on the basis of an 58 
extensive list of preventive measures. We present in this Review 16 recommendations specific to the 59 
intraoperative and postoperative periods. The WHO recommendations were developed with a global 60 
perspective and they take into account the balance between benefits and harms, the evidence 61 
quality level, cost and resource use implications, and patient values and preferences. 62 
 63 
INTRODUCTION 64 
Surgical site infections (SSIs) are largely preventable, but they represent a considerable burden for 65 
health-care systems, particularly in low-income and middle-income countries. For these reasons, and 66 
the fact that no general set of international recommendations exists, WHO prioritised the 67 
development of evidence-based global guidelines for the prevention of SSIs. A panel of international 68 
experts developed recommendations on the basis of predetermined research questions and the 69 
results of related systematic literature reviews. The description of the intended audience for these 70 
recommendations, the methods used, and the first group of recommendations regarding 71 
preoperative preventive measures are provided in paper 1 of this Series,1 which should be read in 72 
conjunction with this Review. We present here the recommendations (table) to be applied in the 73 
intraoperative and postoperative periods. Important topics such as asepsis in the operating room 74 
and sterilisation are not mentioned because they were not the object of formal recommendations, 75 
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but they are included and extensively reviewed in the WHO guidelines, as cornerstones of SSI 76 
prevention. 77 
 78 
RECOMMENDATION 1: PERIOPERATIVE OXYGENATION 79 
The panel recommends that adult patients undergoing general anaesthesia with endotracheal 80 
intubation for surgical procedures should receive an 80% fraction of inspired oxygen (FiO2) 81 
intraoperatively and, if feasible, in the immediate postoperative period for 2–6 h, to reduce the risk 82 
of SSI (strong recommendation, moderate quality of evidence). 83 
Adequate surgical site tissue oxygenation is thought to have a role in preventing SSIs. A high partial 84 
pressure of oxygen in the blood achieved through the administration of high-concentration oxygen 85 
(hyperoxia, defined as oxygen at 80% FiO2) provides more adequate oxygenation at the surgical 86 
incision—particularly at infected tissue,4 which has a lower oxygen tension than non-infected 87 
tissue5—and might enhance oxidative killing by neutrophils.6 We did a systematic review to assess 88 
the effect of high FiO2 (80%) compared with standard FiO2 (30–35%) for the prevention of SSI. 89 
We identified 15 randomised controlled trials (RCTs)7–21 comparing the perioperative administration 90 
of 80% FiO2 with 30–35% FiO2 in adults. We did a meta-analysis that included studies in which 91 
patients underwent general anaesthesia with endo tracheal intubation and mechanical ventilation.7–92 
17 Ventilation control (and therefore the actual administration of FiO2) with a facemask or nasal 93 
cannulae in neuraxial anaesthesia was considered to be a different intervention from mechanical 94 
ventilation. Furthermore, a meta-regression analysis showed that the type of anaesthesia 95 
independently modified the effect of hyperoxygenation. The 11 RCTs included in the meta-analysis 96 
showed that increased perioperative FiO2 is beneficial in reducing SSI compared with standard 97 
perioperative FiO2 (odds ratio [OR] 0·72; 95% CI 0·55–0·94). The quality of the evidence was rated as 98 
moderate. 99 
On the basis of this evidence, patients undergoing general anaesthesia with endotracheal intubation 100 
for surgical procedures should receive 80% FiO2 intraoperatively and, if feasible, for 2–6 h in the 101 
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immediate postoperative period. The expert panel noted that the benefits of this intervention can 102 
be observed only when implemented by both intubation during the operation, and using a high-flux 103 
mask in the immediate postoperative period (figure). The benefits are also maximised when 104 
normothermia and normovolaemia are maintained. In low-resource settings in which medical 105 
oxygen is scarce and its increased use could place a burden on available resources, this 106 
recommendation might not be considered as a priority by policymakers. 107 
 108 
RECOMMENDATION 2: MAINTAINING NORMAL BODY TEMPERATURE (NORMOTHERMIA) 109 
The panel suggests the use of warming devices in the operating room and during the surgical 110 
procedure for patient body warming with the purpose of reducing SSI (conditional recommendation, 111 
moderate quality of evidence). 112 
Hypothermia is defined as a core temperature less than 36°C. It commonly occurs during and after 113 
surgical procedures lasting more than 2 h because of impairment of thermoregulation by anaesthesia, 114 
combined with exposure to a cold environment (the operating room).22,23 Unintended hypothermia is 115 
considered to be an adverse event of general and regional anaesthesia and might be associated with 116 
increased cardiac complications, blood loss due to impaired coagulation, impaired wound healing, 117 
decreased drug metabolism, decreased immune function, and an increased risk of SSI.22,24–27 We did a 118 
systematic review to assess the effectiveness of perioperative body warming on the prevention of 119 
SSIs. 120 
We found two RCTs28,29 comparing the effect of preoperative and intraoperative body warming on SSIs 121 
in adults with no body warming. Meta-analysis showed that body warming was significantly associated 122 
with a reduced risk of SSIs (OR 0·33; 95% CI 0·17–0·62); the quality of the evidence was rated as 123 
moderate. However, in developing countries, the equipment and maintenance costs of electrical 124 
body-warming equipment represent a substantial financial burden, and availability and procurement 125 
are additional issues. Blankets can be considered as a low-cost, effective option in low-resource 126 
settings. 127 
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 128 
RECOMMENDATION 3: USE OF INTENSIVE PROTOCOLS FOR PERIOPERATIVE BLOOD GLUCOSE 129 
CONTROL 130 
The panel suggests the use of protocols for intensive perioperative blood glucose control for both 131 
diabetic and non-diabetic adults undergoing surgical procedures, to reduce the risk of SSI (conditional 132 
recommendation, low quality of evidence). 133 
A rise in blood glucose concentration is commonly observed in the operative and postoperative 134 
periods because of a surgical stress response, resulting in increased secretion of catabolic hormones 135 
(eg, catecholamines or cortisol), inhibition of insulin secretion, and insulin resistance.30 Observational 136 
studies have shown that hyperglycaemia is associated with an increased risk of SSIs in both diabetic 137 
and non-diabetic patients.31–33 Although the importance of perioperative blood glucose control is 138 
agreed upon, there is controversy regarding the best treatment options, the optimal target 139 
concentration of blood glucose, and the optimal timing of glucose control. The concern is due to the 140 
risk of developing hypoglycaemia, which is also associated with increased morbidity and mortality.34–141 
37 We did a systematic review to investigate whether the use of intensive protocols for perioperative 142 
blood glucose control is more effective in reducing the risk of SSI in both diabetic and non-diabetic 143 
patients than conventional protocols with less stringent target blood glucose concentrations. 144 
We identified 15 RCTs38–52 in adults. Overall, an intensive protocol with strict blood glucose target 145 
concentrations was associated with significantly decreased SSI incidence compared with a 146 
conventional protocol (OR 0·43; 95% CI 0·29–0·64). Because of the heterogeneity of the timing of 147 
application of the protocols (intraoperative vs intraoperative-and-postoperative vs postoperative), 148 
study population (patients with diabetes vs patients without diabetes vs mixed population), and the 149 
upper limit of the target concentration of blood glucose (≤110 mg/dL [6·1 mmol/L] vs 110–150 mg/dL 150 
[6·1–8·3 mmol/L]), we decided to do separate meta-analyses for each of these comparisons. No 151 
significant difference in the effect on SSI reduction was observed between studies of patients with 152 
and without diabetes in meta-regression analyses (p=0·590). There was some evidence that the SSI 153 
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reduction effect was smaller in studies that used intensive blood glucose control intraoperatively only 154 
(OR 0·88; 0·45–1·74) compared with studies that used intensive blood glucose controls 155 
postoperatively or both intra operatively and postoperatively (OR 0·37; 0·25–0·55; p=0·049 for 156 
difference between these ORs). 157 
No significant difference was observed (p=0·328) between studies that used low upper limit target 158 
blood glucose concentrations (≤110 mg/dL; 6·1 mmol/L), versus studies with high upper limit 159 
concentrations (110–150 mg/dL; 6·1–8·3 mmol/L). The overall quality of the evidence was rated as 160 
low. Further analysis of adverse events showed no difference between the use of an intensive protocol 161 
and a conventional protocol in the risk of death (OR 0·74; 95% CI 0·45–1·23; p=0·2) or stroke (OR 1·37; 162 
0·26–7·20; p=0·7). However, there was an overall increased risk of hypoglycaemia (OR 5·55; 2·58–163 
11·96). Meta-regression analyses showed no difference in the risk of hypoglycaemia between studies 164 
that used low or high upper limit target blood glucose concentrations (p=0·413). 165 
In conclusion, using a protocol with strict blood glucose target concentrations is associated with a 166 
substantial benefit for the reduction of SSI prevalence, but neither the optimal blood glucose target 167 
concentration nor the perioperative timing of glucose control could be defined. However, it should be 168 
noted that hypoglycaemia is a possible serious side-effect associated with these intensive protocols 169 
and close reliable monitoring of blood glucose concentrations is crucial for this intervention. 170 
 171 
RECOMMENDATION 4: MAINTENANCE OF ADEQUATE CIRCULATING VOLUME CONTROL 172 
(NORMOVOLAEMIA) 173 
The panel suggests the use of goal-directed fluid therapy (GDFT) intraoperatively to reduce the risk of 174 
SSI (conditional recommendation, low quality of evidence). 175 
Adequate intravascular volume is an essential component of tissue perfusion and an important aspect 176 
of tissue oxygenation.53 In unbalanced fluid states—ie, hypovolaemia and hypervolaemia—tissue 177 
oxygenation is compromised and might increase the risk of SSI.54 The optimal type of fluid (colloid or 178 
crystalloid) or strategy of fluid management (goal-directed, liberal, or restrictive) remain controversial 179 
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topics, partly because of the absence of a universal definition of normovolaemia or a standardised 180 
method for its assessment. We did a systematic review to assess whether specific fluid management 181 
strategies for the maintenance of normovolaemia are more effective in reducing the risk of SSI than 182 
standard fluid regimens administered during surgery. 183 
We identified 24 RCTs55–78 comparing specific strategies of fluid management with standard 184 
management. Because of substantial heterogeneity in the type of specific fluid management strategy 185 
used, separate meta-analyses were done for GDFT or restrictive fluid regimens versus standard 186 
regimens in the preoperative, intraoperative, and postoperative periods. GDFT refers to a 187 
haemodynamic treatment based on the titration of fluid and inotropic drugs according to cardiac 188 
output or similar parameters. Restrictive fluid management refers to the administration of a regimen 189 
with a reduced volume of fluids in the bolus or over time, compared with local standard fluid 190 
maintenance. A meta-analysis of 14 RCTs55–68 showed that intraoperative GDFT was significantly 191 
associated with lower incidence of SSIs than standard intraoperative fluid management (OR 0·56; 95% 192 
CI 0·35–0·88). Meta-analysis of five RCTs69–73 showed that restrictive intraoperative fluid management 193 
did not significantly affect SSI incidence compared with standard intraoperative management (OR 194 
0·73; 0·41–1·28). Meta-analysis of two RCTs76,77 showed that postoperative GDFT was associated 195 
with a decreased risk of SSI compared with standard postoperative management (OR 0·24; 0·11–0·52). 196 
One RCT74 showed that preoperative GDFT did not significantly affect SSI incidence compared with 197 
standard preoperative management (OR 0·47; 0·13–1·72). 198 
Considering the evidence (rated as low quality), the panel suggested the use of GDFT intraoperatively 199 
to prevent SSI. Its postoperative use might also be beneficial to reduce SSI. However, restrictive fluid 200 
management and preoperative GDFT were not associated with the reduction of SSI compared with 201 
standard fluid management. 202 
 203 
RECOMMENDATION 5 AND 6: DRAPS AND GOWNS 204 
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The panel suggests that either sterile disposable non-woven or sterile reusable woven drapes and 205 
surgical gowns be used during surgical operations for the purpose of preventing SSI (conditional 206 
recommendation, moderate to very low quality of evidence); and suggests that plastic adhesive incise 207 
drapes with or without antimicrobial properties should not be used (conditional recommendation, 208 
low to very low quality of evidence). 209 
Drapes and gowns are available for single-use or multiple-use, with varying compositions. Adhesive 210 
plastic incise drapes are used on a patient’s skin after surgical site preparation, with or without 211 
antimicrobial impregnation, and the surgeon performs the incision of the drape and the skin 212 
simultaneously. In available guidelines, there are conflicting recommendations on the use of plastic 213 
adhesive drapes, mainly discouraging their use.79 There are no recommendations on the use of single-214 
use or reusable drapes and gowns for the purpose of SSI prevention. We did a systematic review to 215 
investigate the use of sterile disposable or reusable drapes and surgical gowns, and separately the use 216 
of plastic adhesive incise drapes, for the purpose of SSI prevention. 217 
We identified 11 studies80–90 (four RCTs81,86,89,90). Meta-analysis of five studies (one RCT,81 one quasi-218 
RCT,82 and three observational studies80,83,84) comparing sterile disposable non-woven drapes and 219 
gowns with sterile reusable woven drapes and gowns showed no difference in the SSI risk (RCTs, 220 
moderate quality evidence: OR 0·85; 95% CI 0·66–1·09; observational studies, very low quality 221 
evidence: OR 1·56; 0·89–2·72). Meta-analysis of four studies (one RCT,86 one quasi-RCT,85 and two 222 
observational studies87,88) comparing adhesive iodine-impregnated incise drapes with no drapes 223 
showed no difference in the SSI risk (RCTs: OR 2·62; 0·68–10·04; observational studies: OR 0·49; 0·16–224 
1·49). Similarly, meta-analysis of two RCTs89,90 comparing non-impregnated adhesive incise drapes 225 
to no drapes showed no difference in the SSI risk (OR 1·10; 0·68–1·78). The quality of the evidence 226 
was rated low to very low. 227 
Considering the evidence, including potential issues of availability and costs in low-resource settings 228 
and the ecological effect, the expert panel suggested that either sterile disposable non-woven or 229 
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sterile reusable woven drapes and gowns can be used. However, adhesive incise drapes (with or 230 
without antimicrobial properties) should not be used for the purpose of preventing SSI. 231 
 232 
RECOMMENDATION 7: WOUND-PROTECTOR DEVICES 233 
The panel suggests considering the use of wound-protector devices in clean-contaminated, 234 
contaminated, and dirty abdominal surgical procedures for the purpose of reducing the rate of SSIs 235 
(conditional recommendation, very low quality of evidence). 236 
Wound-protector devices (or wound-edge protectors) are comprised of a non-adhesive plastic sheath 237 
attached to a single or double rubber ring that firmly secures the sheath to the wound edges. They 238 
facilitate the retraction of the incision during surgery and are aimed at reducing wound-edge 239 
contamination to a minimum during abdominal surgical procedures. Notably, they have been on the 240 
market despite scarce evidence supporting their usefulness. We did a systematic review to assess the 241 
effectiveness of wound-protector devices for the reduction of SSI risk compared with conventional 242 
wound protection in abdominal surgery. 243 
We found 11 studies (ten RCTs,91–100 and one prospective controlled trial101) in adults. Meta-analysis 244 
showed that the use of a wound-protector device (single-ring or double-ring) was associated with a 245 
significantly lower risk of SSI than with conventional wound protection (OR 0·42; 95% CI 0·28–0·62). 246 
Meta-regression analyses showed no evidence of a difference in the effect between single-ring and 247 
double-ring wound-protector devices or between clean-contaminated, contaminated, or dirty surgery 248 
and other surgery. 249 
Considering the evidence (rated as very low quality), the panel suggests the use of wound-protector 250 
devices in clean-contaminated, contaminated, and dirty abdominal surgical procedures for the 251 
prevention of SSI. The panel highlighted that wound-protector device use should not always be 252 
prioritised in low-resource settings over other interventions that prevent SSI, because of their scarce 253 
availability and associated costs. 254 
 255 
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RECOMMENDATION 8 AND 9: INCISIONAL WOUND IRRIGATION 256 
The panel suggests considering the use of irrigation of the incisional wound with an aqueous povidone-257 
iodine solution before closure for the purpose of preventing SSI, particularly in clean and clean-258 
contaminated wounds (conditional recommendation, low quality of evidence); but the panel suggests 259 
that antibiotic incisional wound irrigation before closure should not be done (conditional 260 
recommendation, low quality of evidence); insufficient evidence was available to recommend for or 261 
against saline irrigation of incisional wounds before closure for the purpose of preventing SSIs. 262 
Intraoperative wound irrigation refers to the flow of a solution across the surface of an open wound. 263 
It is a widely practised procedure and considered to help prevent SSIs.102–104 Among other benefits, 264 
wound irrigation is intended to physically remove cellular debris, surface bacteria, and body fluids, to 265 
dilute possible contamination, and to function as a local antibacterial agent when an antiseptic or 266 
antibiotic agent is used. Practices vary depending on the patient population, the surface of application, 267 
and solutions used. We did a systematic review to investigate whether intraoperative wound irrigation 268 
(with or without active agents or pressured application) affects the incidence of SSI. Studies 269 
investigating the topical application of antibiotics or antiseptics (eg, powder, gels, sponges) were not 270 
included. We also excluded studies in which surgical antibiotic prophylaxis was not administered 271 
appropriately (ie, preoperatively and intravenous) or wound irrigation represented a therapeutic 272 
intervention for a pre-existent infection rather than a prophylactic measure. 273 
We identified 21 RCTs105–125 comparing wound irrigation with no wound irrigation in patients 274 
undergoing various surgical procedures, and the results were substantially heterogeneous. The panel 275 
decided to restrict the recommendation to incisional wound irrigation, because too little (and 276 
heterogeneous) evidence was available to address other applications of irrigation—ie, intraperitoneal 277 
or mediastinal irrigation. 278 
Moderate to very low quality evidence from four studies using irrigation with a saline solution 279 
administered with different methods provided conflicting results.110,113,115,117 Irrigation with saline 280 
solution using pulse pressure or applied with force had a marked benefit in terms of SSI 281 
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reduction.110,115,117 A meta-analysis of seven RCTs105–108 showed a significant benefit of irrigation of the 282 
incisional wound with aqueous povidone-iodine solutions in different concentrations compared with 283 
irrigation with a saline solution (OR 0·31; 95% CI 0 13–0·73; p=0·007). Further stratification according 284 
to the wound contamination class and povidone-iodine solution showed that the effect was 285 
attributable to incisional wound irrigation in clean and clean-contaminated procedures with povidone-286 
iodine 10% and povidone-iodine 0·35%. A meta-analysis of five studies119–121,123,124 showed no 287 
significant difference between antibiotic irrigation of the incisional wound and no irrigation or 288 
irrigation with a saline solution (OR 1·16; 0·64–2·12; p=0·63). 289 
The panel concluded that the evidence was insufficient to recommend for or against saline irrigation 290 
of incisional wounds for the purpose of preventing SSIs. By contrast, incisional wound irrigation with 291 
an aqueous povidone-iodine solution might have a benefit, particularly in clean and clean-292 
contaminated wounds. Finally, antibiotic incisional wound irrigation before closure should not be used 293 
for the purpose of preventing SSI. The expert panel strongly emphasised that this practice is associated 294 
with an unnecessary risk of antimicrobial resistance. 295 
Allergic reactions and metabolic adverse events should be considered as potential harms of iodine 296 
uptake. Although the panel recognises that saline and povidoneiodine solutions are readily available 297 
in most settings, sterile products might be scarce in low-income and middle-income countries. In many 298 
settings, the availability and costs of pulse-pressure devices represent a high financial burden, 299 
including not only their purchase, but also waste disposal, procurement, energy, and machine 300 
maintenance. 301 
 302 
RECOMMENDATION 10: PROPHYLACTIC NEGATIVE-PRESSURE WOUND THERAPY 303 
The panel suggests the use of prophylactic negative-pressure wound therapy (pNPWT) on primarily 304 
closed surgical incisions in high-risk wounds, for the purpose of preventing SSI, while taking resources 305 
into account (conditional recommendation, low quality of evidence). 306 
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pNPWT consists of a closed sealed system connected to a vacuum pump, which maintains negative 307 
pressure on the wound surface. Although used for several other purposes since the late 1990s, it is 308 
also applied on primarily closed surgical incisions to prevent SSIs. We did a systematic review to 309 
establish whether the use of pNPWT is more effective in reducing the risk of SSIs than the use of 310 
conventional wound dressings. 311 
We identified 19 publications describing 20 studies (six RCTs126–130 and 14 observational studies131–144). 312 
Overall, meta-analyses of RCTs and observational studies showed that pNPWT has a significant benefit 313 
in reducing the risk of SSI in patients with a primarily closed surgical incision compared with 314 
conventional postoperative wound dressings (RCTs: OR 0·56; 95% CI 0·32–0·96; observational studies: 315 
OR 0·30; 0·22–0·42). When stratified by type of surgery, this effect was observed in abdominal (nine 316 
observational studies;132–136,140,141,143,144 OR 0·31; 0·19–0·49) and cardiac (two observational 317 
studies;137,138 OR 0·29; 0·12–0·69) surgery, but it was not statistically significant in orthopaedic or 318 
trauma surgery. Stratification by wound contamination class showed a significant benefit in reducing 319 
SSI prevalence with the use of pNPWT in clean surgery (eight observational studies;131,135,137–320 
139,141,142,144 OR 0·27; 95% CI 0·17–0·42) and in clean-contaminated surgery (eight observational 321 
studies;132–134,136,140,141,143,144 OR 0·29; 0·17–0·50). 322 
On the basis of the low-quality evidence available, the panel suggests the use of pNPWT on primarily 323 
closed surgical incisions in high-risk conditions (eg, poor tissue perfusion due to surrounding soft tissue 324 
or skin damage, decreased blood flow, bleeding or haematoma, dead space, or intraoperative 325 
contamination) for the purpose of the prevention of SSIs, taking available resources into account. The 326 
panel highlighted that the use of pNPWT might not be prioritised in low-resource settings compared 327 
with other interventions to prevent SSI considering its poor availability and potential associated costs. 328 
 329 
RECOMMENDATION 11: ANTIMICROBIAL-COATED SUTURES 330 
The panel suggests the use of triclosan-coated sutures to reduce the risk of SSIs, independent of the 331 
type of surgery (conditional recommendation, moderate quality of evidence). 332 
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Sutures with antimicrobial properties were developed with the aim to prevent microbial colonisation 333 
of the suture material in operative incisions. Early studies showed a reduction of the number of 334 
bacteria in vitro and wound infections in animals145–147 using triclosan-coated sutures and this effect 335 
was subsequently confirmed in clinical studies. Several novel antimicrobial coatings are now available, 336 
but still no clinical studies have been done that compare the efficacy with non-coated sutures.148,149 337 
We did a systematic review to assess whether the use of antimicrobial-coated sutures is more effective 338 
in reducing the risk of SSIs than the use of non-coated sutures. 339 
We found 18 studies (13 RCTs150–162 and five cohort studies163–167). All studies investigated triclosan-340 
coated sutures and focused on adult patients, apart from one152 done in a paediatric population. The 341 
overall meta-analysis showed that antimicrobial-coated sutures have a significant benefit in reducing 342 
SSI incidence in patients undergoing surgical procedures compared with non-coated sutures (RCTs: OR 343 
0·72; 95% CI 0·59–0·88; observational studies: OR 0·58; 0·40–0·83). When considering specific types 344 
of sutures, only the meta-analyses of the studies comparing triclosan-coated polyglactin 910 suture 345 
with polyglactin 910 suture featuring a braided suture construction showed that the use of 346 
antimicrobial-coated sutures significantly reduces SSI prevalence compared with the non-coated 347 
sutures (OR 0·62; 0·44–0·88 for RCTs; OR 0·58; 0·37–0·92 for observational studies). In meta-348 
regression analysis, we found no evidence that the effect of antimicrobial coating of sutures differed 349 
between braided and monofilament sutures (p=0·380), or between clean (p=0·690), cardiac (p=0·900), 350 
or abdominal (p=0·832) surgeries and other surgical procedures. 351 
We highlighted that the quality of the evidence was moderate to low and that many studies had 352 
several limitations, including industry sponsorship or conflicts of interest with a commercial entity. On 353 
the basis of the evidence but also considering these limitations, the panel suggests the use of 354 
antimicrobial-coated sutures for the purpose of reducing the risk of SSI. Because the effect appears to 355 
be independent of the type of procedure or wound contamination classification, this recommendation 356 
applies to any type of surgery. Availability and costs should be considered in low-income and middle-357 
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income countries. Further studies are needed also on sutures coated with an alternative antimicrobial 358 
agent to triclosan. 359 
 360 
RECOMMENDATION 12: LAMINAR AIRFLOW VENTILATION SYSTEMS IN THE CONTEXT OF 361 
OPERATING ROOM VENTILATION 362 
The panel suggests that laminar airflow ventilation systems should not be used to reduce the risk of 363 
SSIs for patients undergoing total arthroplasty surgery (conditional recommendation, low to very low 364 
quality of evidence). 365 
Conventional ventilation systems pass air with a mixed or turbulent flow into the operating room. 366 
These systems aim to homogenise the fresh air, the air, and aerosols and particles within the room. 367 
Laminar airflow systems pass the fresh air unidirectionally with a steady velocity and approximately 368 
parallel streamlines to create a zone in which the air, aerosols, and particles within the room are driven 369 
out. Systems with laminar airflow are frequently used in an environment where contamination with 370 
particles is a serious adverse event—eg, orthopaedic implant surgery. However, laminar airflow 371 
systems are complex and expensive and require careful maintenance. In many settings in low-income 372 
countries, neither conventional nor laminar flow systems are affordable or maintained effectively on 373 
a regular basis and often, natural ventilation is the only option. 374 
We did a systematic review to assess whether a laminar airflow ventilation system is more effective 375 
in reducing the risk of SSI than a conventional ventilation system. We also investigated whether fans 376 
or cooling devices and natural ventilation are acceptable alternatives to conventional ventilation for 377 
the prevention of SSI. We only identified one observational study168 that compared natural ventilation 378 
with conventional ventilation in the operating room. No difference was observed in the risk of SSI 379 
following both total hip and knee arthroplasty. One systematic review169 and eight observational 380 
studies168,170–176 comparing laminar airflow with conventional ventilation were identified. Most studies 381 
focused on total hip and knee arthroplasty and only a few single studies were available for other types 382 
of surgery.170,171,173 Meta-analyses showed that laminar airflow ventilation has no benefit compared 383 
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with conventional ventilation in reducing the SSI incidence in total hip (OR 1·29; 95% CI 0·98–1·71) or 384 
knee (OR 1·08; 0·77–1·52) arthroplasty. The quality of the evidence was rated as very low. Considering 385 
these results and associated costs, the expert panel decided to suggest that laminar airflow ventilation 386 
systems should not be used as a preventive measure to reduce the risk of SSI in patients undergoing 387 
total arthroplasty surgery. 388 
 389 
RECOMMENDATION 13 AND 14: ANTIMICROBIAL PROPHYLAXIS IN THE PRESENCE OF A DRAIN AND 390 
OPTIMAL TIMING FOR WOUND DRAIN REMOVAL 391 
The panel suggests not continuing perioperative antibiotic prophylaxis because of the presence of a 392 
wound drain (conditional recommendation, low quality of evidence). They also suggest removing the 393 
wound drain when clinically indicated, but they found no evidence to recommend an optimal time for 394 
wound drain removal (conditional recommendation, very low quality of evidence). 395 
Drainage tubes are widely used in surgery to remove any fluid or blood that collects in the wounds 396 
and cavities created by the surgical procedure and thus might cause complications. However, drains 397 
might adversely affect surgical outcomes—eg, affecting anastomotic healing by causing infection in 398 
the anastomotic area and the abdominal wound. Many systematic reviews investigating the effect of 399 
drains on the related infection risk compared with no wound drainage have been published with 400 
conflicting results. The optimal time for drain removal after surgery might influence this risk, but it 401 
remains unknown. Furthermore, in most cases, antibiotic prophylaxis is continued postoperatively 402 
when a drain is used, but this practice is not evidence-based and raises serious concerns in terms of 403 
contributing to the emergence of antimicrobial resistance. We did a systematic review to investigate 404 
whether prolonged antibiotic prophylaxis in the presence of a wound drain is more effective in 405 
reducing the risk of SSIs than standard perioperative prophylaxis alone. The review also assessed 406 
whether the early removal of wound drains more effectively prevents SSIs than late removal. 407 
Regarding the first question, seven RCTs177–183 were identified. The meta-analysis showed that 408 
prolonged antibiotic prophylaxis in the presence of a wound drain has no benefit in reducing SSI 409 
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compared with perioperative prophylaxis alone (OR 0·79; 95% CI 0·53–1·20). We identified 11 410 
RCTs184–194 comparing early with late removal of closed wound drains. However, there was 411 
heterogeneity in the study definitions for early and late drain removal. For the purposes of the 412 
analysis, early removal was considered to be from postoperative day 1 to day 5. Two main groups 413 
were identified for defining late wound drain removal—ie, drain removal at postoperative day 6 or 414 
later (three studies187,189,192) and removal on the basis of drainage volume (six studies184–415 
187,188,190,191). Studies not falling into these categories were excluded from the analysis. The meta-416 
analysis showed that early drain removal does not affect SSI incidence compared with late removal 417 
(OR 0·86; 0·49–1·50). 418 
On the basis of this low to very low quality evidence, the panel suggests that antibiotic prophylaxis 419 
should not be continued in the presence of a wound drain for the purpose of preventing SSI. Given 420 
the results and very low quality of the evidence about optimal timing for removal, wound drains 421 
should be removed when clinically indicated. 422 
 423 
RECOMMENDATION 15: WOUNDS DRESSINGS 424 
The panel suggests not using any type of advanced dressing over a standard dressing on primarily 425 
closed surgical wounds for the purpose of preventing SSIs (conditional recommendation, low quality 426 
of evidence). 427 
A wide variety of wound dressings are available. Advanced dressings are mainly hydrocolloid, 428 
hydrogels, fibrous hydrocolloid, or polyurethane matrix hydrocolloid dressings and vapour-permeable 429 
films. A Cochrane review195 and its update196 on the effect of dressings for the prevention of SSI found 430 
no evidence to suggest that one dressing type was better than any other. We did a systematic review 431 
to assess whether the use of advanced dressings is more effective in reducing the risk of SSIs than 432 
standard wound dressings. 433 
We identified ten RCTs197–206 in adult patients undergoing various types of surgical procedures. There 434 
were variations in the definition of SSIs, the duration of postoperative follow-up, and in the type of 435 
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dressing (hydrocolloid, hydroactive and silver-impregnated, or polyhexamethalene biguanide-436 
impregnated dressings). Overall, the meta-analysis showed that advanced dressings do not 437 
significantly reduce SSI occurrence compared with standard dressings (OR 0·80; 95% CI 0·52–1·23); 438 
the quality of the evidence was rated as low. In specific meta-analyses, hydrocolloid, silver-439 
impregnated, and hydroactive dressings were non-effective in reducing the risk of SSI compared with 440 
standard dressings. On the basis of the evidence, the panel recommended that advanced dressings 441 
should not be used for the prevention of SSIs. 442 
 443 
RECOMMENDATION 16: POSTOPERATIVE SURGICAL ANTIBIOTIC PROPHYLAXIS PROLONGATION 444 
The panel recommends against the prolongation of surgical antibiotic prophylaxis (SAP) 445 
administration after completion of the operation for the purpose of preventing SSIs (strong 446 
recommendation, moderate quality of evidence). 447 
The preventive effect of the routine use of SAP has long been recognised; however, the necessary 448 
duration of SAP to achieve the desired effect has been a matter of debate. Most guidelines 449 
recommend a maximum postoperative SAP duration of 24 h, but increasing evidence shows that using 450 
only a single preoperative dose (and possible additional intraoperative doses according to the duration 451 
of the operation) might be non-inferior. Despite this, surgeons still often routinely continue SAP up to 452 
several days after surgery, which leads to serious concerns for the risk of antimicrobial resistance. We 453 
did a systematic review to investigate whether prolonged SAP in the postoperative period is more 454 
effective in reducing the risk of SSIs than perioperative prophylaxis (defined as a single dose before 455 
incision and possible intraoperative additional dose[s] according to the duration of the operation). 456 
We found 69 RCTs177–180,183,207–270 investigating the optimal duration of antibiotic prophylaxis in a 457 
variety of surgical procedures. The overall meta-analysis, which pooled studies using any prolonged 458 
SAP regimens, showed no benefit in terms of reducing the SSI incidence compared with a single dose 459 
of antibiotic prophylaxis (OR 0·89; 95% CI 0·77–1·03). However, a meta-analysis of studies showed 460 
that SAP continuation might be beneficial in reducing SSI compared with a single prophylactic dose in 461 
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cardiac (OR 0·43; 0·25–0·76)232,233 and orthognathic (OR 0·30; 0·10–0·88)242–244 surgery. Considering 462 
the low quality of the evidence and the results of the overall meta-analysis (moderate quality), the 463 
expert panel decided to strongly recommend against SAP prolongation, also because of the 464 
widespread risk of antimicrobial resistance. Continuing antibiotic administration in cardiac and 465 
orthognathic surgery has potential benefit, but further well designed RCTs on this topic are needed. 466 
 467 
CONCLUSION 468 
We discuss the evidence for a broad range of intraoperative and postoperative preventive measures 469 
identified by an expert panel as potentially contributing to reducing the risk of SSI. For some of these, 470 
the evidence shows no benefit and the panel advises against the adoption of these interventions, 471 
particularly when considering resource implications or other consequences, such as antimicrobial 472 
resistance. However, the panel identified a range of key measures for SSI prevention to be 473 
implemented in the intraoperative and postoperative periods, together with other preoperative 474 
measures discussed in paper 1 of this Series. Adoption of the recommendations should be facilitated 475 
by sound implementation strategies and practical tools. Notably, careful assessment of feasibility and 476 
cost implications in low-resource settings is needed. 477 
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